Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Fragmin · 3 trials · 2 indications
A successful HD session is defined in terms of efficacy of the drug where the HD session had completed as planned: there was no premature termination due to Grade 3 or 4 clotting or saline flush to prevent the loss of the extracorporeal circuit due to clotting; it was not possible to return the participant's blood or assess the exact extent of clotting. HD sessions which terminated prematurely due to Grade 1 or 2 clotting, safety event, machine failure, or access site displacement were excluded from the analysis. The point estimate and 95% CI were computed based on generalized estimating equation (GEE) model for clustered binomial data.
Major hemorrhages: defined as fatal bleeding, clinically overt bleeding causing a fall in hemoglobin greater than or equal to 20 gram (g)/litre (L) (2 g/ decilitre \[dL\]), clinically overt bleeding leading to transfusion of greater than or equal to 2 units of whole blood or red cells, or symptomatic bleeding in areas of special concern (intracranial, retroperitoneal, intraocular, intraspinal, pericardial, intramuscular with compartmental syndrome, or intraarticular). Minor hemorrhages: defined as bleeding that did not meet the definition of major bleeding.
Major hemorrhages: defined as fatal bleeding, clinically overt bleeding causing a fall in hemoglobin greater than or equal to 20 g/L (2 g/dL), clinically overt bleeding leading to transfusion of greater than or equal to 2 units of whole blood or red cells, or symptomatic bleeding in areas of special concern (intracranial, retroperitoneal, intraocular, intraspinal, pericardial, intramuscular with compartmental syndrome, or intraarticular).
Minor hemorrhages: defined as bleeding that did not meet the definition of major bleeding.
Clinically relevant minor (non-major) bleeding was defined as any bleeding compromising hemodynamics, leading to hospitalization, subcutaneous haematoma more than 25 cm\^2, intramuscular haematoma, epistaxis lasting for more than 5 minutes, spontaneous gingival bleeding, macroscopic hematuria and gastrointestinal hemorrhage (including at least 1 episode of melaena or hematemesis), rectal blood loss, hemoptysis, and any other bleeding with clinical consequences.
Trivial bleeding was defined as all minor bleeding that did not meet the definition of clinically relevant minor bleeding.
University of Texas (UT) system assesses ulcer depth, wound infection and clinical signs of lower-extremity ischemia. UT Wound Classification (1C/2C) was based on grade (0= healed site to 3= penetrating wound to bone or joint) and stage (A= clean wounds to D= ischaemic infected wounds) of wounds. Participants were evaluated at 4 stratums: Stratum 1: Toe pressure\>30 mm of mercury (mmHg) and UT grade and stage 1C. Stratum 2: Toe pressure\<=30 mmHg and UT grade and stage 1C. Stratum 3: Toe pressure\>30 mmHg and UT grade and stage 2C. Stratum 4: Toe pressure\<=30 mmHg and UT grade and stage 2C.
| Arm | Type | Description |
|---|---|---|
| Fragmin | EXPERIMENTAL | Fragmin given according to the flexible dosing regimen outlined in the protocol |
| Active | EXPERIMENTAL | Active study treatment |
| Placebo | PLACEBO_COMPARATOR | Placebo |
| Name | Type | Description |
|---|---|---|
| Fragmin | DRUG | variable dosing regimen |
| Fragmin/ Dalteparin Sodium | DRUG | Pre-filled syringes containing a single dose of 5000 IU Fragmin/ Dalteparin Sodium. |
| Placebo for Fragmin/ Dalteparin Sodium | DRUG | Pre-filled syringes containing a single dose of placebo for 5000 IU Fragmin/ Dalteparin Sodium. |
Inclusion Criteria: * chronic renal failure on hemodialysis Exclusion Criteria: * significant comorbidities that would prevent a patient from completing the trial
Fragmin is being studied for use in chronic renal failure and diabetic foot ulcer. In chronic renal failure, it is being evaluated for use in hemodialysis. In diabetic foot ulcer, it is being studied for the treatment of neuroischaemic foot ulcers in diabetic patients.
Fragmin is being developed by Pfizer, Inc., a biopharmaceutical company traded on the New York Stock Exchange under the ticker symbol PFE.
Fragmin is in Phase 3 clinical development. It has completed Phase 2 and Phase 3 trials, and it remains an investigational drug that is not yet approved for any use.
Fragmin has been studied in three completed clinical trials. NCT00662831 and NCT00765063 evaluated Fragmin in diabetic foot ulcer, and NCT01879618 evaluated Fragmin in hemodialysis for chronic renal failure. All trials have been completed.
Fragmin is a brand name for dalteparin, a low molecular weight heparin. It is being studied for its effects in diabetic foot ulcers and in hemodialysis for chronic renal failure.